Article: Targeted therapy for renal cell carcinoma: a prospective study
| creativeworkseries.issn | JNMA Print ISSN: 0028-2715; Online ISSN: 1815-672X | |
| dc.contributor.author | Joshi, Robin | |
| dc.contributor.author | Rawal, Sudhir | |
| dc.creator.affiliation | Kathmandu Medical College, Kathmandu, Nepal. | |
| dc.creator.affiliation | Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India. | |
| dc.date.accessioned | 2026-10-01T05:34:45Z | |
| dc.date.available | 2026-10-01T05:34:45Z | |
| dc.date.issued | 2015 | |
| dc.description.abstract | Abstract Introduction: Our study aims to evaluate the use of targeted therapy in metastatic renal cell carcinoma. Methods: This is a prospective study done over three years from December 2010 to December, 2013. Out of Forty seven patients of metastatic renal cell carcinoma 8(neo-adjuvant cases) were excluded and 39 were included in this study. All patients received Tyrosine kinase inhibitor, sunitinib therapy (50 mg OD, 4/2 scheme). All 39 patients underwent radical nephrectomy prior to sunitinib therapy. Patients were followed up every cycle for their clinical symptoms following sunitinib therapy and every 3 months with chest X-ray, ultra-sonography and bone scan. CT scan was done if needed. A RECIST criterion was used to evaluate the complete, partial and no tumor response. Results: The median survival was 28.5 months (CI 9.253-47.7) and progression free survival (PFS) was 9.16 months(CI 6.08-12.23).According to RECIST, stable disease was found in 6 patients till date and a complete response in two patients. Clear cell histology was found in 30(76.9%) patients, papillary variety in 6(15.39%) patients, chromophobe type was seen in one patient and rest had mixed sarcomatoid papillary and rhabdoid clear cell variety. Twenty four patients (61.5%) had multiple metastases. Most frequent metastasis was seen in lungs in 14 patients (36%) and bone in 12 patients (31%).Metastases were also seen in draining lymph nodes, adrenals, omentum,skin, liver, and brain. Conclusions: In our cohort, use of sunitinib showed similar outcome to previously published articles. Our study supports the use of sunitinib in metastatic renal cell carcinoma. Keywords: Metastatic renal cell carcinoma; Sunitinib; Tyrosine kinase inhibitor. | |
| dc.identifier.doi | https://doi.org/10.31729/jnma.2767 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/7936 | |
| dc.language.iso | en_US | |
| dc.publisher | Nepal Medical Association | |
| dc.subject | Metastatic renal cell carcinoma | |
| dc.subject | Sunitinib | |
| dc.subject | Tyrosine kinase inhibitor | |
| dc.title | Targeted therapy for renal cell carcinoma: a prospective study | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Original Article | |
| oaire.citation.endPage | 88 | |
| oaire.citation.startPage | 83 | |
| relation.isJournalIssueOfPublication | 9310ef88-c5b8-41fa-a2c1-77bada91af00 | |
| relation.isJournalIssueOfPublication.latestForDiscovery | 9310ef88-c5b8-41fa-a2c1-77bada91af00 | |
| relation.isJournalOfPublication | e6e146a0-0ece-4aba-aa0a-6ccfbd10a12a |